Attention: This platform is in beta mode. Expect some changes and adjustments.

AI Market Mood: Stock Dashboard

GLYC


Fundamental

Company: Crescent Biopharma Inc
Sector: Healthcare
Industry: Biotechnology
Country: USA
Exchange: NASD
Index: -
P/E: -
EPS (ttm): -45.72
Insider Own: 10.44%
Shs Outstand: 0.65M
Perf Week: -3.56%
Market Cap: 180.88M
Forward P/E: -
EPS next Y: -3.28
Insider Trans: 0.00%
Shs Float: 0.58M
Perf Month: -17.57%
Enterprise Value: 175.27M
PEG: -
EPS next Q: -1.76
Inst Own: -
Short Float: -
Perf Quarter: -42.84%
Income: -29.49M
P/S: -
EPS this Y: 93.52%
Inst Trans: -
Short Ratio: -
Perf Half Y: -48.15%
Sales: 0.00M
P/B: 2.49
EPS next Y Percentage: 14.30%
ROA: -146.71%
Short Interest: -
Perf YTD: -47.71%
Book/sh: 5.23
P/C: 32.24
EPS next 5Y: 58.90%
ROE: -182.66%
52W High: 63.00 -79.33%
Perf Year: -58.00%
Cash/sh: 0.40
P/FCF: -
EPS past 3/5Y: 21.89% 15.18%
ROIC: -873.60%
52W Low: 11.06 17.72%
Perf 3Y: -80.05%
Dividend Est.: -
EV/EBITDA: -
Sales past 3/5Y: - -
Gross Margin: -
Volatility W: 11.28%
Volatility M: 15.83%
Perf 5Y: -96.75%
Dividend TTM: -
EV/Sales: -
EPS Y/Y TTM: 21.04%
Oper. Margin: -
ATR (14): 1.93
Perf 10Y: -98.22%
Dividend Ex-Date: -
Quick Ratio: 2.29
Sales Y/Y TTM: -100.00%
Profit Margin: -
RSI (14): 35.87
Recom: 1.00
Dividend Gr. 3/5Y: - -
Current Ratio: 2.29
EPS Q/Q: 78.20%
SMA20: -12.28%
Beta: 1.52
Target Price: 25.67
Payout: -
Debt/Eq: 0.00
Sales Q/Q: -
SMA50: -31.12%
Rel Volume: 2.16
Prev Close: 13.14
Employees: 26
LT Debt/Eq: 0.00
Earnings: May 01
SMA200: -46.48%
Avg Volume: 57.82K
Price: 13.02
IPO: Jan 10, 2014
Option/Short: No / Yes
EPS/Sales Surpr.: -39.77% -
Trades:
Volume: 124,892
Change: -0.91%

Technical:


Latest News:

Glycobiology/Glycomics Market 2024 Growth Parameters – Thermo Fisher Scientific, Agilent ... somewhat bullish
TMO A EW WAT BRKR SIAL 7986JP PROZ DHR 7701JP

Summary: A new research report titled Global Glycobiology/Glycomics Market provides an in-depth analysis of a global market summarizing key uses, growth analysis, industry trends, and forecasts to 2032. The report offers a detailed picture of the current industrial situation incorporating authentic and anticipated market estimates in terms of value and volume. The report also includes a full analysis of raw material sourcing, significant suppliers, raw material price patterns, and an examination of the industrial chain.

Full article
2024-09-19T05:48:31Z
Capital One Financial Comments on GlycoMimetics, Inc.'s Q1 2024 Earnings (NASDAQ:GLYC) somewhat bearish
GLYC

Summary: Capital One Financial issued Q1 2024 EPS estimates for GlycoMimetics with a 'Equal Weight' rating. The consensus estimate for GlycoMimetics' full-year earnings is ($0.54) per share. Several brokerages commented on GLYC, with StockNews.com downgrading it and HC Wainwright maintaining a 'neutral' rating.

Full article
2024-05-09T10:51:04Z
Dow Launches Bio-Circular and Circular Propylene Glycol Solutions in North America somewhat bullish
DOW

Summary: Dow (NYSE: DOW) launches two new sustainable varieties of propylene glycol solutions in North America, featuring bio-circular and circular feedstocks, aiming to offer high-performance products with sustainability benefits.

Full article
2024-05-07T17:18:24Z